Atrium C-Qur Hernia Mesh Cases Selected for Initial Bellwether Trial Pool

|

With hundreds of Atrium C-Qur lawsuits pending in the federal court system, each involving similar allegations that individual suffered painful complications from the hernia mesh, a group of 16 cases have been selected for an initial discovery pool, which will be eligible for early trial dates in the litigation.

Atrium C-Qur (pronounced โ€œsecureโ€) was a widely used hernia repair product, which was introduced in March 2006, featuring a unique design that involved a polypropylene mesh with an Omega-3 fatty acid (O3FA) gel coating. While this was designed to reduce scar tissue formation, while promoting fixation of the mesh to the abdominal wall, the C-Qur patch has been linked to a large number of reported problems, including inflammatory responses, bowel adhesions and other painful complications.

Nearly 500ย product liability complaints have been filed in the federal court system over problems with Atrium C-Qur mesh, claiming that the manufacturer sold an unreasonably dangerous and defective hernia repair system, which often results in the need for additional complex procedures to remove the patch months or even years after it is implanted.

Is there a hernia mesh lawsuit? Find out if you qualify for a hernia mesh lawsuit settlement payout.
Is there a hernia mesh lawsuit? Find out if you qualify for a hernia mesh lawsuit settlement payout.

Given similar questions of fact and law raised in the complaints, the U.S. Judicial Panel on Multidistrict Litigation (JPML) establishedย consolidated pretrial proceedings for all Atrium C-Qur hernia mesh casesย in December 2016, centralizing all claims before U.S. District Judge Landya McCafferty in the District of New Hampshire to reduce duplicative discovery into common issues, avoid conflicting pretrial rulings and to serve the convenience of the parties, witnesses and the judicial system.

In a joint notice (PDF) filed on August 9, plaintiffs and defendants identified a group of 16 cases that have been selected for the initial bellwether pool. This group will subsequently be narrowed down to a smaller group of representative cases, which will be eligible for the first Atrium C-Qur trial date, scheduled to begin in February 2020.

Following initial discovery in these cases, the group will be pared down to eight claims by March 1, 2019, with Plaintiffs selecting four and Defendants selecting four, which will continue with case-specific discovery and expert discovery, which is to be completed by September 20, 2019. Daubert motions on challenges to the admissibility of expert testimony will be filed by October 18, 2019, and responses are due by November 1, 2019, according to the order, which indicates that the first โ€œbellwetherโ€ trial will begin on February 19, 2020.

As part of the coordinated MDL proceedings before Judge McCafferty, the parties are scheduled to meet for a status conference on Thursday. According to joint agenda (PDF) submitted late last week, the parties also intend to address with the court a recently filed motion to extend jurisdictional discovery and briefing deadlines.

While the outcomes of these โ€œbellwetherโ€ trials will not be binding on other claims, the process is designed to facilitate potentialย hernia mesh settlementsย that may be necessary to avoid the need for hundreds of individual trials in various U.S. District Courts nationwide following the coordinated MDL proceedings.


0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

An Abbott spinal cord stimulator lawsuit filed by three women says the product was defectively designed, inappropriately approved by the FDA, and left them with severe injuries, worsening pain and the need for removal surgery.
A Georgia couple’s lawsuit claims the makers of Dupixent failed to provide adequate warnings about the risk of mycosis fungoides, a type of T-cell lymphoma.
In a joint statement, plaintiffs and defendants in AngioDynamics port catheter lawsuits have laid guidelines for what types of cases should be selected to serve as potential bellwether trials.